文献速递类风湿关节炎

老年起病类风湿关节炎治疗抵抗性滑膜炎与影像学进展增加:前瞻性观察纵向早期关节炎队列研究

Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2020-05-15

该前瞻性观察纵向早期关节炎队列研究纳入140例早期RA患者(起病年龄<60岁为YORA 99例,≥60岁为EORA 41例),在传统免疫抑制治疗前及6个月后行超声引导下滑膜活检。结果显示EORA患者超声滑膜增厚和能量多普勒滑膜炎及SvdH评分更高,EORA独立关联6个月治疗反应差(OR=0.28)和12个月影像学进展(OR=4.08)。

要点

  • EORA患者男性更多,常表现为突发性风湿性多肌痛样起病和关节外表现。
  • EORA治疗前后DAS28-ESR相似,但超声滑膜炎和SvdH评分更高。
  • EORA独立关联6个月治疗反应差和12个月影像学进展。

核心结论

  • 早期EORA表现不同且总体预后较YORA更差,临床、组织学、超声和影像学结局均更差。

研究设计与样本

  • 前瞻性观察纵向早期关节炎队列研究,纳入140例早期RA(<12个月)患者,YORA 99例,EORA 41例。
  • 患者在传统免疫抑制治疗前及6个月后行超声引导下滑膜活检,前瞻性收集临床、超声和影像学数据。

主要发现

  • EORA患者男性更常见,多表现为突发性风湿性多肌痛样起病和关节外表现。
  • 治疗前后两组DAS28-ESR相似,但EORA患者超声滑膜增厚(p<0.05)、能量多普勒滑膜炎(p<0.01)和SvdH评分(p<0.001)更高。
  • EORA独立关联6个月治疗反应差(OR=0.28,p=0.047)和12个月影像学进展(OR=4.08,p=0.029)。
  • 治疗前滑膜病理类型、滑膜炎评分和细胞浸润相似,6个月时YORA中少免疫纤维样病理类型趋向更常见(p=0.093)。
  • YORA患者所有滑膜炎参数显著改善(p<0.001),而EORA仅滑膜炎(p<0.05)、衬里下巨噬细胞(p<0.05)和T细胞评分(p<0.05)轻度下降,衬里巨噬细胞、B细胞或浆细胞无显著变化。

关键数值与推荐

  • 临床反应定义为6个月时DAS28-ESR<3.2。
  • 影像学进展定义为12个月时SvdH评分增加≥1单位。

临床怎么用

  • 对EORA患者应加强超声和影像学监测,警惕治疗抵抗和影像学进展。
  • EORA患者可能需要更积极的治疗策略,但需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical outcomes in elderly-onset rheumatoid arthritis (EORA), starting after the age of 60, are conflicting. Thus, we aimed to investigate in a unique biopsy-driven, treatment-naïve early arthritis cohort, the relationship between synovial pathobiology of elderly- (EORA) and younger-onset rheumatoid arthritis (YORA) patients through clinical, imaging and treatment response outcome-measures. METHODS: Patients (n = 140) with early RA (<12months) starting before (YORA, n = 99) or after (EORA, n = 41) age 60 had an ultrasound-guided synovial biopsy prior to conventional immunosuppressive therapy and after 6 months. Clinical, ultrasound and radiographic data were collected prospectively and compared between groups and against immunohistological features. Using multivariate logistic regression, we determined predictors of clinical response (disease activity score-28-erythrocyte sedimentation rate [DAS28-ESR]<3.2) at 6 months and radiographic progression (≥1-unit-increase in Sharp van der Heijde [SvdH] score) at 12 months. RESULTS: EORA patients were more frequently male and presented most commonly with an abrupt, polymyalgia rheumatica-like onset and extra-articular features. Both before and after treatment, DAS28-ESR was similar but ultrasound synovial-thickening (p<0.05) and power-Doppler (p<0.01) synovitis and SvdH (p<0.001) scores were higher in EORA patients. EORA was independently associated with poor treatment response at 6 months (OR=0.28, p = 0.047) and radiographic progression at 12 months (OR=4.08, p = 0.029). Synovial pathotype, synovitis scores and cellular infiltration were similar before treatment, but a pauci-immune-fibroid pathotype tended to be more common in YORA at 6 months (p = 0.093). Moreover, YORA patients had a marked improvement of all synovitis parameters (p<0.001), whereas EORA presented only mild decreases in synovitis (p<0.05), sublining macrophage (p<0.05) and T cell scores (p<0.05), with no significant changes in lining macrophages, B cells or plasma cells. CONCLUSION: Early EORA presents differently and has a worse overall prognosis than YORA, with poorer clinical, histological, ultrasonographic and radiographic outcomes.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Romão VC, Humby F, Kelly S, et al. Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study. Semin Arthritis Rheum. 2020. PMID: 32531503. doi:10.1016/j.semarthrit.2020.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。